New data for AbbVie's eight-week pan-genotypic HCV regimen

AbbVie Inc. (NYSE:ABBV) said an eight-week regimen of ABT-493 plus ABT-530 led to SVR12 rates of 97-98% in HCV genotype 1, 2 and 3 patients in the ongoing Phase II SURVEYOR-I and SURVEYOR-II

Read the full 331 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE